Formation of the HIV-1 Latent Reservoir
Formation of the HIV-1 Latent Reservoir
批准号:
10013718
负责人:
Ronald I Swanstrom
金额:
$65.93万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-02-13 至 2025-01-31
关键词:
AddressAntigensAntiviral TherapyApoptosisArchivesAwardBehaviorBiologicalBloodBlood CellsCD4 Positive T LymphocytesCellsClinicalCollaborationsDataData AnalysesEmodinEnvironmentEventFundingFutureGenomeHIVHIV-1HolidaysIndividualInfectionInflammationInflammatoryInternationalInterphase CellLymph Node TissueLymphoid TissueNatureNorth CarolinaPatternPharmaceutical PreparationsPopulation HeterogeneityRecording of previous eventsResearchRestSamplingSouth AfricaSwedenT-LymphocyteT-Lymphocyte SubsetsTimeTissuesUnited States National Institutes of HealthUniversitiesVeinsViralViral reservoirVirusVirus LatencyVirus ReplicationWomanWorkantiretroviral therapybasecell typeclinical research sitecohortcytokineexperienceinsightlatent HIV reservoirmenpreventsuperinfectionviral DNAviral rebound
中文摘要
项目摘要
HIV-1潜伏库的性质最近被重新定义。我们最近的研究表明,
大部分储库(平均70%)在治疗开始时形成,并且可能在治疗开始时形成。这
是一个非常不同的看法水库从历史上的一个水库开始形成后,
感染,并不断形成。病毒复制的抑制改变了宿主环境,
细胞,其中一些被感染,变得长寿。我们还证明了这对病毒DNA也是如此,
虽然大部分都有缺陷因此,潜在的水库是标志着一组细胞过渡到长寿
开始治疗时的状态,无论其感染状态如何。这种关于潜在储层的新观点
在本申请中解决的一些关键问题。首先,如果水库是在不同的
它的形成是否有着相同的历史?我们将通过两种选择来解决这个问题
潜伏性储库的定义:治疗中止期间病毒反弹,以及假定的“深层”储库
在肠道和淋巴结组织中。其次,由于我们最初的观察是在一组女性中进行的,我们
也会问同样的问题关于男性储层形成的时间。第三,自治疗开始以来,
确定大部分储层形成的时间,我们将检查储层是否被破坏,
在药物假期期间进行改革,然后重新开始治疗。第四,我们将确定
T细胞的分化状态,所述T细胞具有在免疫启动之前早期形成的储库的亚群。
疗法第五,我们将跟踪携带病毒的细胞的分化状态,
储库作为治疗抑制病毒复制。总的来说,这些研究将使我们对
当水库形成时,无论人们如何定义水库,在男性和女性中。他们还将
显示了在重新引入先前在很大程度上阻止了的炎症状态后,
水库的形成。最后,他们将开始探索形成T细胞的分化状态。
早期水库和细胞因子环境面临病毒复制,然后分化状态
这些T细胞在抑制治疗期间转变为长寿命储存库的一部分。这些研究将提供
一个概念框架,为未来的新策略,以限制水库形成时,治疗开始。
英文摘要
PROJECT ABSTRACT
The nature of the HIV-1 latent reservoir has recently been redefined. Our recent work has shown that a large
majority of the reservoir (on average 70%) is formed near, and presumably at, the time of therapy initiation. This
is a very different view of the reservoir from the historical one where the reservoir starts to be formed early after
infection and forms continuously. Suppression of viral replication changes the host environment to allow certain
cells, some of which are infected, to become long lived. We have also shown this is true for viral DNA even
though most of it is defective. Thus, the latent reservoir is marking a set of cells that transition to a long-lived
state with the initiation of therapy irrespective of their infection status. This new view of the latent reservoir begs
a number of key questions that are addressed in this application. First, if the reservoir is defined in a different
way does its formation have the same history? We will address this question by looking at two alternative
definitions of the latent reservoir: rebound virus during therapy discontinuation, and a putative "deep" reservoir
in both gut and lymph node tissue. Second, since our initial observations were made in a cohort of women, we
will ask the same question about the timing of reservoir formation in men. Third, since the initiation of therapy
determines when a majority of the reservoir is formed, we will examine whether the reservoir is disrupted and
reforms over a period of a drug holiday followed by therapy re-initiation. Fourth, we will determine the
differentiation state of the T cells harboring the subset of the reservoir that forms early prior to the initiation of
therapy. Fifth, we will follow the differentiation state of cells harboring the viruses that will form the long-lived
reservoir as therapy suppresses viral replication. Collectively these studies will complete our understanding of
when the reservoir forms, regardless of how one defines the reservoir, in both men and women. They will also
show the stability of the reservoir after reintroducing an inflammatory state that had previously largely prevented
the formation of the reservoir. Finally, they will start to explore the differentiation state of the T cells that form the
early reservoir and the cytokine environment present in the face of viral replication, then the differentiation state
these T cells transition to as part of the long-lived reservoir during suppressive therapy. These studies will provide
a conceptual framework for future new strategies to limit reservoir formation at the time of therapy initiation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
27th Annual United States Conference on HIV/AIDS (USCHA)
-
批准号:10760611
-
项目类别:
-
资助金额:$18.68万
-
财政年份:2023
-
负责人:Ronald I Swanstrom
-
依托单位:
25th Annual United States Conference on HIV/AIDS (USCHA)
-
批准号:10323910
-
项目类别:
-
资助金额:$7.45万
-
财政年份:2021
-
负责人:Ronald I Swanstrom
-
依托单位:
Formation of the HIV-1 Latent Reservoir
-
批准号:10552552
-
项目类别:
-
资助金额:$57.42万
-
财政年份:2020
-
负责人:Ronald I Swanstrom
-
依托单位:
Formation of the HIV-1 Latent Reservoir
-
批准号:10343734
-
项目类别:
-
资助金额:$59.14万
-
财政年份:2020
-
负责人:Ronald I Swanstrom
-
依托单位:
HIV Evolution Defines Virus-Host/Drug Interactions In Viremic and Aviremic People
-
批准号:10180893
-
项目类别:
-
资助金额:$65.88万
-
财政年份:2018
-
负责人:Ronald I Swanstrom
-
依托单位:
HIV Evolution Defines Virus-Host/Drug Interactions In Viremic and Aviremic People
-
批准号:10412103
-
项目类别:
-
资助金额:$64.79万
-
财政年份:2018
-
负责人:Ronald I Swanstrom
-
依托单位:
Identifying A New Class of HIV Maturation Inhibitors
-
批准号:9529507
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2017
-
负责人:Ronald I Swanstrom
-
依托单位:
Biological Properties of HIV-1 V3 Evolutionary Variants
-
批准号:9321715
-
项目类别:
-
资助金额:$39.6万
-
财政年份:2016
-
负责人:Ronald I Swanstrom
-
依托单位:
Timing of establishment of the HIV latent reservoir in subtype C infected women
-
批准号:8838888
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2015
-
负责人:Ronald I Swanstrom
-
依托单位:
Timing of establishment of the HIV latent reservoir in subtype C infected women
-
批准号:8997446
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2015
-
负责人:Ronald I Swanstrom
-
依托单位:
Timing of establishment of the HIV latent reservoir in subtype C infected women
-
批准号:9212096
-
项目类别:
-
资助金额:$35.0万
-
财政年份:2015
-
负责人:Ronald I Swanstrom
-
依托单位:
Administrative Core
-
批准号:8708736
-
项目类别:
-
资助金额:$95.9万
-
财政年份:2014
-
负责人:Ronald I Swanstrom
-
依托单位:
Development of novel methods to exploit next gen sequencing for HIV
-
批准号:8603615
-
项目类别:
-
资助金额:$20.52万
-
财政年份:2013
-
负责人:Ronald I Swanstrom
-
依托单位:
Development of novel methods to exploit next gen sequencing for HIV
-
批准号:8709990
-
项目类别:
-
资助金额:$19.0万
-
财政年份:2013
-
负责人:Ronald I Swanstrom
-
依托单位:
HIV-1 Persistence in the CNS and Myeloid Cells
-
批准号:8655557
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2013
-
负责人:Ronald I Swanstrom
-
依托单位:
HIV-1 Persistence in the CNS and Myeloid Cells
-
批准号:8544680
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2013
-
负责人:Ronald I Swanstrom
-
依托单位:
Administrative Core
-
批准号:8531830
-
项目类别:
-
资助金额:$58.31万
-
财政年份:2013
-
负责人:Ronald I Swanstrom
-
依托单位:
HIV-1 Persistence in the CNS and Myeloid Cells
-
批准号:9047320
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2013
-
负责人:Ronald I Swanstrom
-
依托单位:
HIV-1 Persistence in the CNS and Myeloid Cells
-
批准号:9212200
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2013
-
负责人:Ronald I Swanstrom
-
依托单位:
HIV Tropism, Persistence, Inflammation and Neurocognition in Therapy Initiation
-
批准号:8140805
-
项目类别:
-
资助金额:$92.11万
-
财政年份:2011
-
负责人:Ronald I Swanstrom
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: